Notice NOT-OD-25-011 from the NIH Guide for Grants and Contracts

Notice NOT-HD-24-034 from the NIH Guide for Grants and Contracts

Notice NOT-AR-24-020 from the NIH Guide for Grants and Contracts

Notice NOT-HS-25-003 from the NIH Guide for Grants and Contracts

Notice NOT-HS-25-004 from the NIH Guide for Grants and Contracts

Notice NOT-RM-24-013 from the NIH Guide for Grants and Contracts

Notice NOT-OD-24-179 from the NIH Guide for Grants and Contracts

Notice NOT-LM-24-004 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-24-038 from the NIH Guide for Grants and Contracts. The NIH Blueprint for neuroscience is soliciting applications to pilot the establishment of an integrated resource for users to explore, analyze and download processed deidentified human brain single-cell transcriptomics and epigenomics data that is harmonized across reference and disease datasets. The resource will generate a unified cell type taxonomy, provide users with a draft annotatable cell-type nomenclature, and the ability to map community generated single cell omics data to the taxonomy. This pilot will lay the groundwork for an expanded and sustained effort to increase utility and accessibility of human cell-type classification data across multiple NIH consortia. BD

Notice NOT-MH-25-020 from the NIH Guide for Grants and Contracts

Notice NOT-MH-25-030 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-25-123 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

Funding Opportunity PA-25-121 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

Notice NOT-MH-25-025 from the NIH Guide for Grants and Contracts

Notice NOT-NS-25-003 from the NIH Guide for Grants and Contracts

Notice NOT-MH-25-035 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-304 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of this NOFO is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" r "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer control and prevention. Research applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this NOFO encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

Funding Opportunity RFA-CA-24-033 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI), solicits applications from institutions/organizations that propose to maintain or establish Network Lead Academic Participating Sites (LAPS) for the NCI National Clinical Trials Network (NCTN). The NCTN Network LAPS will provide scientific leadership by helping to develop and conduct clinical trials in association with one or more adult Network Groups and will contribute substantial accrual to clinical trials conducted across the entire NCTN.

Funding Opportunity RFA-CA-24-031 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI), solicits applications from institutions/organizations that propose to maintain Network Group Statistics and Data Management Centers (SDMCs) for the NCI National Clinical Trials Network (NCTN). The NCTN Network SDMCs will provide statistical expertise for effective scientific design, conduct, and data management of clinical trials led by the associated NCTN Network Group Operations Center.

Notice NOT-AG-24-065 from the NIH Guide for Grants and Contracts